PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.

Ost, Piet; Siva, Shankar; Brabrand, Sigmund; Dirix, Piet; Liefhooghe, Nick; Otte, François-Xavier; Gomez-Iturriaga, Alfonso; Everaerts, Wouter; Shelan, Mohamed; Conde-Moreno, Antonio; López Campos, Fernando; Papachristofilou, Alexandros; Guckenberger, Matthias; Scorsetti, Marta; Zapatero, Almudena; Villafranca Iturre, Ana-Elena; Eito, Clara; Couñago, Felipe; Muto, Paolo; Van De Voorde, Lien; ... (2024). PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. European urology oncology, 7(3), pp. 462-468. Elsevier 10.1016/j.euo.2023.09.007

Text 1-s2.0-S2588931123001992-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (789kB)

BACKGROUND

Treatment recommendations for patients with limited nodal recurrences are lacking, and different locoregional treatment approaches are currently being used.

OBJECTIVE

The aim of this trial is to compare metastasis-directed therapy (MDT) with or without elective nodal pelvic radiotherapy (ENRT).

DESIGN, SETTING, AND PARTICIPANTS

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) is an international, phase 2, open-label, randomized, superiority trial (ClinicalTrials.gov identifier: NCT03569241). Patients diagnosed with positron emission tomography-detected pelvic nodal oligorecurrence (five or fewer nodes) following radical local treatment for prostate cancer were randomized in a 1:1 ratio between arm A (MDT and 6 mo of androgen deprivation therapy [ADT]) and arm B (ENRT [25 × 1.8 Gy] with MDT and 6 mo of ADT).

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

We report the secondary endpoint acute toxicity, defined as worst grade ≥2 Common Terminology Criteria for Adverse Events v4.0 gastrointestinal (GI) or genitourinary (GU) toxicity within 3 mo of treatment. The chi-square test was used to compare toxicity between treatment arms. We also compare the quality of life (QoL) using the European Organisation for Research and Treatment of Cancer QLQ C30 and PR25 questionnaires.

RESULTS AND LIMITATIONS

Between June 2018 and April 2021, 196 patients were assigned randomly to MDT or ENRT. Ninety-seven of 99 patients allocated to MDT and 93 of 97 allocated to ENRT received per-protocol treatment. Worst acute GI toxicity proportions were as follows: grade ≥2 events in three (3%) in the MDT group versus four (4%) in the ENRT group (p = 0.11). Worst acute GU toxicity proportions were as follows: grade ≥2 events in eight (8%) in the MDT group versus 12 (13%) in the ENRT group (p = 0.95). We observed no significant difference between the study groups in the proportion of patients with a clinically significant QoL reduction from baseline for any subdomain score area.

CONCLUSIONS

No clinically meaningful differences were observed in worst grade ≥2 acute GI or GU toxicity or in QoL subdomains between MDT and ENRT.

PATIENT SUMMARY

We found no evidence of differential acute bowel or urinary side effects using metastasis-directed therapy and elective nodal radiotherapy for the treatment of patients with a pelvic lymph node recurrence.

Interest & Impact

Downloads

0 since deposited on 12 Oct 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item